Category News

Marinus Pharmaceuticals inicia programa de acesso mundial para CV de suspensão oral do ZTALMY

Marinus Pharmaceuticals inicia programa de acesso mundial para CV de suspensão oral do ZTALMY® (ganaxolona) –Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), uma empresa farmacêutica especializada no desenvolvimento de terapêuticas inovadoras para tratar distúrbios convulsivos, anunciou hoje o início do Marinus Access Program…

Read MoreMarinus Pharmaceuticals inicia programa de acesso mundial para CV de suspensão oral do ZTALMY

Gilead and Kite Oncology Present Data Demonstrating CAR T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023

Gilead and Kite Oncology Present Data Demonstrating CAR T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023 Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will share 29 presentations, including 10 oral…

Read MoreGilead and Kite Oncology Present Data Demonstrating CAR T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023

Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy

Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy Novartis today announced positive topline results from the interim analysis of the ongoing pivotal Phase III ALIGN study (NCT04573478) of…

Read MoreNovartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy

Phase III RUBY trial of Jemperli plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer

Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer GSK plc today announced positive headline results from a planned analysis of Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO…

Read MorePhase III RUBY trial of Jemperli plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer

Boehringer Ingelheim’s SPEVIGO wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award

Boehringer Ingelheim’s SPEVIGO wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award Boehringer Ingelheim today announced that SPEVIGO® (spesolimab) has been recognized as Best Orphan/Rare Diseases Solution of 2023 by the Galien Foundation. The Prix Galien USA Award was…

Read MoreBoehringer Ingelheim’s SPEVIGO wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award

Immunis Chairman Dr. Hans Keirstead to Present at BIO Europe Conference in Germany

Immunis Chairman Dr. Hans Keirstead to Present at BIO Europe Conference in Germany Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, proudly announces that its Chairman, Dr. Hans Keirstead, will present at BIO Europe in…

Read MoreImmunis Chairman Dr. Hans Keirstead to Present at BIO Europe Conference in Germany

Imfinzi plus Lynparza reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer

Imfinzi plus Lynparza reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer Positive results from the primary analysis of the DUO-E Phase III trial showed that Imfinzi (durvalumab) plus platinum-based chemotherapy, followed by…

Read MoreImfinzi plus Lynparza reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer

REGENERON BUILDS ON TOGETHER FOR CHANGE™ INITIATIVE WITH FIVE-YEAR, $5 MILLION COMMITMENT TO FUEL THE STEM TALENT PIPELINE IN NASHVILLE, TN

REGENERON BUILDS ON TOGETHER FOR CHANGE™ INITIATIVE WITH FIVE-YEAR, $5 MILLION COMMITMENT TO FUEL THE STEM TALENT PIPELINE IN NASHVILLE, TN TARRYTOWN, N.Y., Oct. 18, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a five-year, $5 million strategic investment to bolster Nashville, Tennessee’s science, technology,…

Read MoreREGENERON BUILDS ON TOGETHER FOR CHANGE™ INITIATIVE WITH FIVE-YEAR, $5 MILLION COMMITMENT TO FUEL THE STEM TALENT PIPELINE IN NASHVILLE, TN